The US Food and Drug Administration (FDA) has approved a new faster-acting, mealtime version of insulin aspart (Fiasp, Novo Nordisk) for the treatment of type 1 and type 2 diabetes in adults. Fiasp (insulin aspart injection 100 units/mL) is a new formulation of the company’s NovoLog, to which niacinamide (vitamin B3) has been added to help increase the speed of the initial insulin absorption. Fiasp is designed to be dosed at the beginning of a meal or within 20 minutes after starting a meal, as the insulin will appear in the blood approximately 2.5 minutes after dosing. More info coming next issue.